Bioventus Inc.

03/05/2026 | Press release | Distributed by Public on 03/05/2026 06:40

Initial Registration Statement for Employee Benefit Plan (Form S-8)


As filed with the Securities and Exchange Commission on March 5, 2026
Registration No. 333-
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM S-8
REGISTRATION STATEMENT
UNDER
THE SECURITIES ACT OF 1933
Bioventus Inc.
(Exact name of registrant as specified in its charter)
Delaware 81-0980861
(State or other jurisdiction
of incorporation or organization)
(I.R.S. Employer
Identification Number)
4721 Emperor Boulevard, Suite 100
Durham, North Carolina 27703
(Address of principal executive offices) (Zip code)
Bioventus Inc. 2021 Incentive Award Plan
Bioventus Inc. 2021 Employee Stock Purchase Plan
(Full title of the plans)
Robert E. Claypoole
President and Chief Executive Officer
Bioventus Inc.
4721 Emperor Boulevard, Suite 100
Durham, North Carolina 27703
(919) 474-6700
(Name and address of agent for service) (Telephone number, including area code, of agent for service)
With copies to:
Lorna A. Knick, Esq.
Nicholas C. Massey, Esq.
Wyrick Robbins Yates & Ponton LLP
4101 Lake Boone Trail, Suite 300
Raleigh, North Carolina 27607
Telephone: (919) 781-4000
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.
Large accelerated filer
☐
Accelerated filer
☒
Non-accelerated filer
☐
Smaller reporting company
☐
Emerging growth company
☒
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of Securities Act. ☒



EXPLANATORY NOTE
Pursuant to General Instruction E to Form S-8, this Registration Statement on Form S-8 is being filed for the purpose of registering an additional 3,729,800 shares of Bioventus Inc.'s (the "Registrant") Class A common stock to be issued pursuant to the Bioventus Inc. 2021 Incentive Award Plan (the "2021 Plan") and an additional 670,977 shares of the Registrant's Class A common stock to be issued pursuant to the Bioventus Inc. 2021 Employee Stock Purchase Plan (the "2021 ESPP") and for which Registration Statements of the Registrant on Form S-8 relating to the same employee benefit plans are effective.
INCORPORATION BY REFERENCE OF CONTENTS OF REGISTRATION STATEMENT ON FORM S-8
The contents of the Registration Statements on Form S-8 (File No. 333-252981, File No. 333-263496, File No. 333-271310, File No. 333-278100, and File No. 333-285698 ), filed with the Securities and Exchange Commission on February 11, 2021, March 11, 2022, April 18, 2023, March 20, 2024, and March 11, 2025, respectively, relating to the 2021 Plan and the 2021 ESPP, as amended, or as modified or superseded pursuant to Rule 412 under the Securities Act of 1933, as amended, are incorporated herein by reference.
Part II
INFORMATION REQUIRED IN THE REGISTRATION STATEMENT
Item 8. Exhibits
Exhibit no.
Description
4.1
4.2
4.3
5.1*
Opinion of Wyrick Robbins Yates & Ponton LLP.
23.1*
Consent of Grant Thornton, Independent Registered Public Accounting Firm.
23.2*
Consent of Wyrick Robbins Yates & Ponton LLP (included in Exhibit 5.1).
24.1*
Power of Attorney (included on signature page).
99.1
99.2
107.1*
Filing Fee Table.
* Filed herewith
SIGNATURES
Pursuant to the requirements of the Securities Act of 1933, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Durham, State of North Carolina, on March 5, 2026.
BIOVENTUS INC.
Date: March 5, 2026 By: /s/ Robert E. Claypoole
Robert E. Claypoole
President, Chief Executive Officer and Director (Principal Executive Officer)



POWER OF ATTORNEY
Each person whose signature appears below hereby constitutes and appoints Robert E. Claypoole and Mark L. Singleton, or each of them singly, with full power to act without the other, such person's true and lawful attorneys-in-fact and agents, with full power of substitution and re-substitution, for him or her and in his or her name, place and stead, in any and all capacities, to sign this registration statement and any and all amendments, including post-effective amendments to this registration statement, and to file the same, with exhibits and schedules thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary or desirable to be done in connection therewith as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or any of them, or their or his or her substitute or substitutes may lawfully do or cause to be done by virtue hereof.
Pursuant to the requirements of the Securities Act of 1933, as amended, this registration statement has been signed by the following persons in the capacities and on the dates indicated.


Name
Date
Title
/s/ Robert E. Claypoole March 5, 2026 President, Chief Executive Officer and Director
(Principal Executive Officer)
Robert E. Claypoole
/s/ Mark L. Singleton March 5, 2026 Senior Vice President and Chief Financial Officer
(Principal Financial Officer and Principal Accounting Officer)
Mark L. Singleton
/s/ William A. Hawkins III March 5, 2026 Chairman
William A. Hawkins III
/s/ John A. Bartholdson March 5, 2026 Director
John A. Bartholdson
/s/ Patrick J. Beyer
March 5, 2026 Director
Patrick J. Beyer
/s/ Philip G. Cowdy March 5, 2026 Director
Philip G. Cowdy
/s/ Ajay Dhankhar March 5, 2026 Director
Ajay Dhankhar
/s/ Mary Kay Ladone March 5, 2026 Director
Mary Kay Ladone
/s/ Michelle McMurry-Heath March 5, 2026 Director
Michelle McMurry-Heath
/s/ Guido J. Neels March 5, 2026 Director
Guido J. Neels
/s/ Guy P. Nohra March 5, 2026 Director
Guy P. Nohra
/s/ Susan M. Stalnecker March 5, 2026 Director
Susan M. Stalnecker
/s/ Martin P. Sutter March 5, 2026 Director
Martin P. Sutter

Bioventus Inc. published this content on March 05, 2026, and is solely responsible for the information contained herein. Distributed via EDGAR on March 05, 2026 at 12:41 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]